Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "brand"

1111 News Found

UFlex posts Q1 FY26 PAT at Rs. 58 Cr
News | August 17, 2025

UFlex posts Q1 FY26 PAT at Rs. 58 Cr

The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization


Cohance Lifesciences reports 13% revenue growth in Q1 FY26
News | August 16, 2025

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site


Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
News | August 13, 2025

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY


Akums reports Q1 FY26 PAT at Rs. 65 Cr
News | August 09, 2025

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals


Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr
News | August 09, 2025

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25


Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
News | August 06, 2025

Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter


Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
News | August 05, 2025

Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr

The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore


Johnson & Johnson submits additional data to FDA on psoriatic arthritis
News | August 03, 2025

Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study


GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
News | August 03, 2025

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results